Literature DB >> 12709798

Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.

Claudio Gambini1, Massimo Conte, Gabriella Bernini, Paola Angelini, Andrea Pession, Paolo Paolucci, Alberto Donfrancesco, Edvige Veneselli, Katia Mazzocco, Gian Paolo Tonini, Lizzia Raffaghello, Carlo Dominici, Adriana Morando, Francesca Negri, Anna Favre, Bruno De Bernardi, Vito Pistoia.   

Abstract

The aim of this study was to investigate the histological, immunohistochemical and molecular features of a series of children with neuroblastic tumors (NTs) and opsoclonus-myoclonus syndrome (OMS). Of 1187 children (age 0-15 years) with previously untreated NTs registered between 1979 and 1995, 15 (1.3%) had OMS at presentation. The majority of patients showed favorable biological characteristics, such as lack of amplification of the neuroblastoma-associated avian myelocytomatosis homolog MYCN oncogene and aneuploid nuclear DNA content. Tumor histology was reviewed according to the International Neuroblastoma Pathology Classification. Histology of the 15 cases of NTs with OMS was ganglioneuroblastoma, intermixed, in 10 patients; ganglioneuroma, maturing, in 1; and neuroblastoma in 4. Of 15 tumors, 12 (10 ganglioneuroblastomas, 2 neuroblastomas) showed abundant interstitial or perivascular lymphoid infiltrates, the latter often organized in secondary lymphoid follicles. The three remaining cases had only minimal infiltrates. A review of 91 cases of age- and stage-matched neuroblastic tumors not associated with OMS tested as controls showed that the degree of lymphoid infiltration was significantly lower than that detected in OMS-related tumors. Furthermore, lymphoid follicles were always present in the latter tumors, whereas they were detected only in a few ganglioneuroma, intermixed tumors from the control group. In conclusion, ganglioneuroblastoma, intermixed subtype, lack of MYCN amplification, aneuploid DNA content and presence of lymphoid infiltrates may contribute to favorable prognosis in NTs associated with OMS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709798     DOI: 10.1007/s00428-002-0747-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  44 in total

1.  Neurological sequelae of the dancing eye syndrome.

Authors:  K R Pohl; J Pritchard; J Wilson
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

2.  Opsoclonus/myoclonus: paraneoplastic syndrome of neuroblastoma.

Authors:  A Janss; J Sladky; J Chatten; J Johnson
Journal:  Med Pediatr Oncol       Date:  1996-04

3.  Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

4.  Opsomyoclonus and neuroblastoma. Response to ACTH.

Authors:  B G Nickerson; J J Hutter
Journal:  Clin Pediatr (Phila)       Date:  1979-07       Impact factor: 1.168

5.  Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.

Authors:  E Rudnick; Y Khakoo; N L Antunes; R C Seeger; G M Brodeur; H Shimada; R B Gerbing; D O Stram; K K Matthay
Journal:  Med Pediatr Oncol       Date:  2001-06

6.  Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance.

Authors:  D W Hedley; M L Friedlander; I W Taylor
Journal:  Cytometry       Date:  1985-07

7.  Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome.

Authors:  W G Mitchell; S R Snodgrass
Journal:  J Child Neurol       Date:  1990-04       Impact factor: 1.987

8.  Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome.

Authors:  E Hiyama; T Yokoyama; T Ichikawa; K Hiyama; M Kobayashi; Y Tanaka; K Ueda; Y Tanaka; H Yano
Journal:  Cancer       Date:  1994-09-15       Impact factor: 6.860

9.  Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G.

Authors:  M J Petruzzi; P A de Alarcon
Journal:  J Pediatr       Date:  1995-08       Impact factor: 4.406

10.  Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma.

Authors:  P S Koh; J G Raffensperger; S Berry; M B Larsen; H S Johnstone; P Chou; S R Luck; M Hammer; S L Cohn
Journal:  J Pediatr       Date:  1994-11       Impact factor: 4.406

View more
  8 in total

1.  Paraneoplastic Opsoclonus-Myoclonus-Ataxia (OMA) syndrome in an adult patient with esthesioneuroblastoma.

Authors:  Dominique Van Diest; Hendrik De Raeve; Jozef Claes; Paul M Parizel; Dirk De Ridder; Patrick Cras
Journal:  J Neurol       Date:  2008-02-04       Impact factor: 4.849

2.  Paraneoplastic cerebellar ataxia associated with anti-Hu antibodies and benign ganglioneuroma.

Authors:  Roberto Fancellu; Elena Corsini; Giorgio Bernardi; Paolo Buzzo; Maria Luisa Ferrari; Eleonora Lamantea; Alberto Garaventa; Mauro Truini; Sandro Salvarani
Journal:  Funct Neurol       Date:  2014 Oct-Dec

Review 3.  Soluble HLA-G: Are they clinically relevant?

Authors:  Vito Pistoia; Fabio Morandi; Xinhui Wang; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2007-07-31       Impact factor: 15.707

4.  Paraneoplastic brain stem encephalitis.

Authors:  Franz Blaes
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

5.  The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review.

Authors:  Alexis B Rothenberg; Walter E Berdon; Giulio J D'Angio; Darrell J Yamashiro; Robert A Cowles
Journal:  Pediatr Radiol       Date:  2009-05-09

6.  APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures.

Authors:  Guillaume Morcrette; Theo Z Hirsch; Elise Badour; Jill Pilet; Stefano Caruso; Julien Calderaro; Yoann Martin; Sandrine Imbeaud; Eric Letouzé; Sandra Rebouissou; Sophie Branchereau; Sophie Taque; Christophe Chardot; Catherine Guettier; Jean-Yves Scoazec; Monique Fabre; Laurence Brugières; Jessica Zucman-Rossi
Journal:  Oncoimmunology       Date:  2019-03-28       Impact factor: 8.110

Review 7.  Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.

Authors:  Thomas Rossor; E Ann Yeh; Yasmin Khakoo; Paola Angelini; Cheryl Hemingway; Sarosh R Irani; Gudrun Schleiermacher; Paramala Santosh; Tim Lotze; Russell C Dale; Kumaran Deiva; Barbara Hero; Andrea Klein; Pedro de Alarcon; Mark P Gorman; Wendy G Mitchell; Ming Lim
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-03-08

Review 8.  Paraneoplastic neurological syndromes.

Authors:  Jérôme Honnorat; Jean-Christophe Antoine
Journal:  Orphanet J Rare Dis       Date:  2007-05-04       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.